key: cord-0953516-dlbgyhi7
authors: Wang, Ying; Shi, Li; Wang, Yadong; Yang, Haiyan
title: An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients
date: 2020-05-27
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.05.063
sha: 12fac3d3190296e40ff173b8d86a78ed460e840f
doc_id: 953516
cord_uid: dlbgyhi7

nan

J o u r n a l P r e -p r o o f ("laboratory" or "clinical") and ("mortality" or "outcome")). Articles reporting AST and ALT levels for both non-survival and survival COVID-19 patients were included.

Articles with potential overlapping reports were excluded (by checking the hospital where the patients came from, the author's organization and other information). The mean and standard deviation were estimated using the sample size, median and interquartile range (IQR) [2] . The pooled effects were presented as standardized mean difference (SMD) and 95% confidence interval (CI). Heterogeneity was checked using the I 2 statistic. We used Stata 11.2 (StataCorp, College Station, TX) to perform the analysis, and P < 0.05 was considered significant.

We found a total of 966 records, and 741 remained after the removal of duplicates. 42 remained after reading the title and abstract. After reading the full text, we excluded 35 studies that did not report AST or ALT levels for both non-survival and survival COVID-19 patients, or reported patients may overlap with other articles.

Finally, seven eligible studies were enrolled in this meta-analysis [3] [4] [5] [6] [7] [8] [9] . Data were collected from patients admitted to Jinyintan Hospital, Hankou and Caidian branch of J o u r n a l P r e -p r o o f

The ALT values showed similar result (SMD = 0.35, 95% CI: 0.13-0.57, P = 0.002; I 2 = 70.4%, P = 0.002) (Fig. 1B) . The results of the leave-one-out sensitivity analysis indicated any single study had no obvious effects on the combined SMD, suggesting our results were robust (Fig. 1C and 1D) . Begg's test (All P > 0.05) and Egger's test (All P > 0.05) suggest no significant publication bias.

In summary, AST and ALT should be considered as predictors of clinical outcomes such as mortality in COVID-19 patients based on the last data. To reach a definitive conclusion, more studies with large sample size are needed to validate the association between the levels of AST and ALT and the risk of mortality in COVID-19 patients in the future. 

Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. European journal of internal medicine

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan